Now, researchers are close to a potential explanation for this double whammy at the molecular level.
They found that DNA sustains more damage and gets “fixed” less often when blood sugar levels are high compared to when blood sugar is at a normal, healthy level, thereby increasing one’s cancer risk.
“It’s been known for a long time that people with diabetes have as much as a 2.5-fold increased risk for certain cancers. These cancers include ovarian, breast, kidney and others,” says Dr. John Termini, a professor at City of Hope, a research and treatment center for cancer and diabetes in Duarte, Calif. “As the incidence of diabetes continues to rise, the cancer rate will likely increase, as well.”
Scientists have suspected that the elevated cancer risk for diabetics arises from hormonal dysregulation.
“In people with Type 2 diabetes, their insulin is not effectively carrying glucose into cells,” Termini explains. “So the pancreas makes more and more insulin, and they get what’s called hyperinsulinemia.”
In addition to controlling blood glucose levels, the hormone insulin can stimulate cell growth, possibly leading to cancer, Termini says.
“Also, most people with Type 2 diabetes are overweight, and their excess fat tissue produces higher levels of adipokines than those at a healthy weight,” explains Termini. “These hormones promote chronic inflammation, which is linked to cancer.”
Termini indicates the most common idea is that the increased cancer risk has to do with hormones, and while he says that’s probably part of it, there hasn’t been a lot of solid evidence to prove it.
Termini and his team had a different idea.
He wondered if the elevated blood glucose levels seen in diabetes could harm DNA, making the genome unstable, which could lead to cancer.
So he and his colleagues looked for a specific type of damage in the form of chemically modified DNA bases, known as adducts, in tissue culture and rodent models of diabetes.
Indeed, they found a DNA adduct, called N2-(1-carboxyethyl)-2′-deoxyguanosine, or CEdG, that occurred more frequently in the diabetic models than in normal cells or mice.
What’s more, high glucose levels interfered with the cells’ process for fixing it.
“Exposure to high glucose levels leads to both DNA adducts and the suppression of their repair, which in combination could cause genome instability and cancer,” Termini says.
Recently, Termini and colleagues completed a clinical study that measured the levels of CEdG, as well as its counterpart in RNA (CEG), in people with Type 2 diabetes.
As in mice, people with diabetes had significantly higher levels of both CEdG and CEG than people without the disease.
The researchers didn’t stop there. They wanted to determine the molecular reasons why the adducts weren’t being fixed properly by the cells.
They identified two proteins that appear to be involved: the transcription factor HIF1α and the signaling protein mTORC1, which both show less activity in diabetes.
HIF1α activates several genes involved in the repair process.
“We found that if we stabilize HIF1α in a high-glucose environment, we increase DNA repair and reduce DNA damage,” Termini says. “And mTORC1 actually controls HIF1α, so if you stimulate mTORC1, you stimulate HIF1α.”
According to Termini, several drugs that stimulate HIF1α or mTORC1 already exist.
The researchers plan to see if these drugs decrease cancer risk in diabetic animal models and if so, they will test them in humans.
Termini notes that metformin, a common diabetes medication that helps lower blood glucose levels, also stimulates DNA repair.
“We’re looking at testing metformin in combination with drugs that specifically stabilize HIF1α or enhance mTORC1 signaling in diabetic animal models,” he says.
In the meantime, a more immediate way for diabetics to reduce their cancer risk could be better control of their blood sugar. “That sounds like such an easy solution, but it’s extremely difficult for most people to maintain glycemic control,” Termini says.
The researchers will present their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition.
The researchers acknowledge support and funding from the National Institutes of Health.